- Corporate website
| 
News
Press Releases
Follow us on :
21/05/12
Stallergenes remains committed to the recognition of innovative pharmaceutical companies and has joined G5 Health
04/05/12
Stallergenes announces positive clinical results for its house dust mites immunotherapy tablet
Results of a clinical study (VO67.10) of the house dust mites sublingual immunotherapy tablet, conducted in an Environmental Exposure Chamber (EEC).
02/04/12
Stallergenes has identified two candidate biomarkers of early efficacy of allergen immunotherapy
21/03/12
Stallergenes continues its strategic international expansion with the successful registration in Canada of Oralair™ tablet for grass pollen
19/03/12
2011 Annual Results
Strong profitability supporting international expansion
• Sales up 9%
• Net profit up 20%
• Net cash of € 70 Million
01/09/11
First half-year results 2011
Substantial increase in profitability: profit before R&D at 40% of sales, operating profit up 20%, net profit at 20% of sales
30/05/11
Stallergenes strenghthens its board of directors with the appointment of 3 new members: Jean-Luc Belingard, Gabriela Camboni and Patrick Langlois.
Antony, France; 30 May 2011 – 18pm
24/05/11
With the inauguration of its new site, Stallergenes continues its development and creates value in France
Category: Group activities
Antony (France), 24 May 2011 - Stallergenes S.A. announces the inauguration of its new administrative headquarters, located in Antony in the Hauts-de-Seine (92) area of France.
18/05/11
Stallergenes obtains a Marketing Authorization for Oralair® in Australia
Category: Products
The Australian health authority, the Therapeutic Goods Administration (TGA), has approved the grass pollen sublingual immunotherapy tablet, Oralair® in adult and pediatric indications.
16/03/11
2010 Financial results: further increase in profit margins and strong cash generation
Sales up 12%,
Operating profit up 40%,
Net profit up 39%,
Cash generation >€50m,
Net cash of nearly €60m,
Proposed dividend of € 0.75 (up 36%)
20/01/11
Stallergenes becomes world's leading producer of grass pollens and house dust mites
Antony, France (20 January 2011) Stallergenes S.A. announces the opening of its new raw materials production unit in Amilly, le Loiret (France).
10/11/10
Stallergenes welcomes Ares Life Sciences as a new reference shareholder
Stallergenes’ Works Council having returned a positive consultative opinion, Wendel and Ares Life Sciences proceeded to sign a firm transfer agreement.
06/09/10
Stallergenes and Shionogi sign exclusive partnership agreementsfor immunotherapy tablets in Japan
26/08/10
First half-year results 2010
Excellent 1st half-year 2010 performance: Growth in France and internationally +13%, very strong net profit growth +51%, free cash flow growth +90%
28/06/10
Persistent efficacy demonstrated after a year on Actair® followed by a 2nd treatment-free year
Category: Products, Group activities
The persistence of the effect of sublingual allergen immunotherapy in perennial allergic rhinitis triggered by house dust mites has been demonstrated.
21/06/10
Staloral® mites 300 clinical study in China: the efficacy of sublingual immunotherapy demonstrated in moderate asthma due to mites.
Category: Products, Group activities
Results of a phase III clinical trial (VO55.06) conducted in China.
19/04/10
Positive results for Oralair® phase III trial in the USA
Category: Products, Group activities
First results of the VO61.08 clinical trial conducted in the USA on the sublingual grass pollen immunotherapy tablet, Oralair®.
16/03/10
2009 Annual results
Further profit margin growth and significant cash generation:
- Sales up 13%, operating profit up 15%, net profit up 17%
- Record free cash flow of € 17.5 million (X 3.7)
- Net cash position turned positive
- Proposed...
07/12/09
Very positive 3-year results of the long-term study
Category: Products, Group activities
These results provide confirmation of the clinical relevance of Oralair.
27/11/09
Stallergenes is granted a marketing authorization for Oralair in Europe
Category: Group activities, Products
Obtention of the European approval in both adults and children through a Mutual Recognition Procedure.
16/09/09
Immunotherapy tablet containing recombinant allergen of birch pollen: positive results for a phase IIb/III trial
Category: Products
First results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen.
27/08/09
A brand name for the 2nd sublingual desensitization tablet produced by Stallergenes
The tablet for allergic rhinitis caused by exposure to dust mites has been given the following brand name: “ACTAIR”
26/08/09
First half-year 2009: performance ahead of expectations
Net profit up 11%, Strong research and investment effort, Positive net financial position, Annual growth guidance maintained at 10%
15/07/09
Strong sales growth in 1st half-year: up 12%, Full-year guidance maintained
2nd quarter growth remained high at 9% (organic 8%), but slowed down compared with the very strong start of the year. Sales growth over the first half-year remained strong at 12% (organic 11%).
29/04/09
House dust mites desensitization tablets: Positive results from a phase IIb/III clinical trial
Category: Products
Release of the first year outcome of the VO 57.07 clinical study on a sublingual house dust mite desensitization tablet.
24/03/09
2008 : A strong performance
Strong growth in results, Sales up 16%, Net profit up 17%
Sound financial position
Proposed increase in dividend
24/03/09
Exclusive partnership with Solvay Pharmaceuticals in Russia and the CIS
Category: Partnership
Signing of an exclusive partnership agreement for the promotion and distribution of Stallergenes diagnostic and treatment products
24/03/09
Tablets coordinated within the Stalair® program
Category: Products
The development of Stallergenes tablet-form pharmaceutical products will now be coordinated within a program dubbed “STALAIR®”.
19/01/09
Oralair® Grasses obtains a pediatric Market Authorisation in Germany
Pediatric extension of the indications for Stallergenes sublingual tablets for desensitization to grass pollens.